[
  {
    "id": 331,
    "question": "The most common first presentation of CJD",
    "option_a": "movement",
    "option_b": "Psychiatry",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAfter a cardiac arrest\u2014especially in a smoker complicated by hypotension and requiring intubation\u2014the brain undergoes a period of global ischemia. The subsequent delayed neurological complaints such as chronic headaches and dizziness are most consistent with a hypoxic-ischemic injury rather than acute derangements like hypercapnia or vascular phenomena like vasospasm.\n\n**Pathophysiology**\n\nDuring cardiac arrest, cerebral blood flow ceases, leading to widespread neuronal hypoxia. Hypotension exacerbates this effect, and upon resuscitation, reperfusion injury (with production of free radicals and inflammatory mediators) may occur. This results in delayed neuronal death and white matter changes\u2014phenomena that are part of hypoxic-ischemic encephalopathy or delayed post-hypoxic leukoencephalopathy. Neither hypercapnia (which is an acute effect due to ventilation issues) nor vasospasm (more typically linked with subarachnoid hemorrhage) explains the delayed symptom picture in this patient.\n\n**Clinical Correlation**\n\nPatients recovering from cardiac arrest can develop chronic neurological deficits. In this case, persistent headache and dizziness a month later suggest that the brain suffered an ischemic insult with subsequent reperfusion injury. Such deficits are aligned with the areas of the brain that are most vulnerable to low oxygen states.\n\n**Diagnostic Approach**\n\nThe evaluation of post-cardiac arrest patients with chronic neurological symptoms usually involves brain imaging (MRI with diffusion-weighted imaging can reveal watershed or diffuse white matter changes) and sometimes EEG. Differential diagnoses include post-hypoxic encephalopathy, subtle infarcts from embolic events, or metabolic encephalopathy. Clinical context and imaging help differentiate these entities.\n\n**Management Principles**\n\nManagement is largely supportive. First-line measures include neurorehabilitation and symptomatic treatments for headaches and dizziness. There is no established pharmacological therapy to reverse hypoxic neuronal loss. In pregnant or lactating patients, conservative symptomatic management is emphasized, ensuring that agents (e.g., acetaminophen for headache) chosen are safe and that neurorehabilitative strategies are adapted appropriately.\n\n**Option Analysis**\n\nOption A (Hypercapnia) deals with acute ventilation issues and would present with acute rather than chronic symptoms. Option B (Vasospasm) is classically seen in the setting of subarachnoid hemorrhage, not following a cardiac arrest. Option C is intended to refer to the mechanism of hypoxic-ischemic injury (even though the option text was missing), which is the correct pathogenesis in this scenario.\n\n**Clinical Pearls**\n\n\u2022 Delayed neurological deficits after cardiac arrest are most commonly due to hypoxic, not hypercapnic, injury.  \u2022 Reperfusion injury is a key contributor to delayed symptomatology post-resuscitation.  \u2022 MRI with DWI is useful in detecting early hypoxic changes.\n\n**Current Evidence**\n\nRecent studies have focused on targeted temperature management during and after cardiac arrest as a means to reduce reperfusion injury. Advances in neuroimaging have enhanced early detection of hypoxic-ischemic changes, and ongoing research is evaluating neuroprotective agents for post-resuscitation care.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "id": 332,
    "question": "Alzheimer Dementia most commonly related gene mutation",
    "option_a": "APP",
    "option_b": "APO.B",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAfter a cardiac arrest\u2014especially in a smoker complicated by hypotension and requiring intubation\u2014the brain undergoes a period of global ischemia. The subsequent delayed neurological complaints such as chronic headaches and dizziness are most consistent with a hypoxic-ischemic injury rather than acute derangements like hypercapnia or vascular phenomena like vasospasm.\n\n**Pathophysiology**\n\nDuring cardiac arrest, cerebral blood flow ceases, leading to widespread neuronal hypoxia. Hypotension exacerbates this effect, and upon resuscitation, reperfusion injury (with production of free radicals and inflammatory mediators) may occur. This results in delayed neuronal death and white matter changes\u2014phenomena that are part of hypoxic-ischemic encephalopathy or delayed post-hypoxic leukoencephalopathy. Neither hypercapnia (which is an acute effect due to ventilation issues) nor vasospasm (more typically linked with subarachnoid hemorrhage) explains the delayed symptom picture in this patient.\n\n**Clinical Correlation**\n\nPatients recovering from cardiac arrest can develop chronic neurological deficits. In this case, persistent headache and dizziness a month later suggest that the brain suffered an ischemic insult with subsequent reperfusion injury. Such deficits are aligned with the areas of the brain that are most vulnerable to low oxygen states.\n\n**Diagnostic Approach**\n\nThe evaluation of post-cardiac arrest patients with chronic neurological symptoms usually involves brain imaging (MRI with diffusion-weighted imaging can reveal watershed or diffuse white matter changes) and sometimes EEG. Differential diagnoses include post-hypoxic encephalopathy, subtle infarcts from embolic events, or metabolic encephalopathy. Clinical context and imaging help differentiate these entities.\n\n**Management Principles**\n\nManagement is largely supportive. First-line measures include neurorehabilitation and symptomatic treatments for headaches and dizziness. There is no established pharmacological therapy to reverse hypoxic neuronal loss. In pregnant or lactating patients, conservative symptomatic management is emphasized, ensuring that agents (e.g., acetaminophen for headache) chosen are safe and that neurorehabilitative strategies are adapted appropriately.\n\n**Option Analysis**\n\nOption A (Hypercapnia) deals with acute ventilation issues and would present with acute rather than chronic symptoms. Option B (Vasospasm) is classically seen in the setting of subarachnoid hemorrhage, not following a cardiac arrest. Option C is intended to refer to the mechanism of hypoxic-ischemic injury (even though the option text was missing), which is the correct pathogenesis in this scenario.\n\n**Clinical Pearls**\n\n\u2022 Delayed neurological deficits after cardiac arrest are most commonly due to hypoxic, not hypercapnic, injury.  \u2022 Reperfusion injury is a key contributor to delayed symptomatology post-resuscitation.  \u2022 MRI with DWI is useful in detecting early hypoxic changes.\n\n**Current Evidence**\n\nRecent studies have focused on targeted temperature management during and after cardiac arrest as a means to reduce reperfusion injury. Advances in neuroimaging have enhanced early detection of hypoxic-ischemic changes, and ongoing research is evaluating neuroprotective agents for post-resuscitation care.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "id": 333,
    "question": "Case of stroke within window NIHSS was 3, next step in rx?",
    "option_a": "DAPT",
    "option_b": "TPA",
    "option_c": "Thrombectomy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn acute ischemic stroke management, the overall goal is to restore perfusion and prevent further ischemic injury. The treatment choice depends on factors including the time window, stroke severity measured by the NIH Stroke Scale (NIHSS), and whether deficits are disabling. A NIHSS of 3 generally indicates a minor stroke, and if the deficits are non\u2010disabling, aggressive thrombolytic therapy may not be warranted.\n\n**Pathophysiology**\n\nIschemic strokes occur from occlusion of cerebral arteries leading to brain tissue ischemia. In mild strokes, the clot may be smaller, and collateral circulation may limit the extent of injury. The risk in these patients is not only the initial infarct but also early recurrent events. Dual antiplatelet therapy (DAPT) works by inhibiting platelet aggregation, thereby reducing the chance of clot extension or new embolic events.\n\n**Clinical Correlation**\n\nPatients with a minor stroke (NIHSS 3) often present with subtle neurological deficits that do not significantly impair function. In such cases, intravenous thrombolysis (tPA) is not automatically indicated unless even a minor deficit is considered disabling. DAPT is favored in non\u2010disabling minor strokes to reduce the risk of early recurrence.\n\n**Diagnostic Approach**\n\nDiagnosis begins with prompt neuroimaging (often a non\u2010contrast CT scan) to rule out hemorrhage, followed by vascular imaging as needed. Differential diagnoses include transient ischemic attack (TIA), migraine, and seizure-related deficits. The clinical context and imaging help distinguish these conditions from an ischemic stroke.\n\n**Management Principles**\n\nFirst-line management for acute ischemic stroke within the treatment window involves IV tPA in patients with disabling deficits. However, for minor, non-disabling strokes (NIHSS 3 and not functionally impairing), the current evidence supports the use of DAPT (commonly aspirin plus clopidogrel) for early secondary prevention. Thrombectomy is reserved for large vessel occlusions. In the context of pregnancy or lactation, aspirin is generally considered safe, although clopidogrel data are limited and should be used if the benefits outweigh the risks.\n\n**Option Analysis**\n\nOption A (DAPT) is correct for non-disabling minor strokes. Option B (TPA) is recommended for patients with disabling symptoms irrespective of stroke severity; however, in a minor, non-disabling stroke, the risks of thrombolysis may outweigh the benefits. Option C (Thrombectomy) is reserved for large vessel occlusion strokes and is not indicated in a minor stroke with an NIHSS of 3.\n\n**Clinical Pearls**\n\n1) In minor, non-disabling strokes, careful assessment is needed to decide against thrombolysis even when within the window. 2) Short-term use of DAPT has been shown to reduce early recurrence in minor stroke. 3) The decision-making must incorporate both the NIHSS and the functional impact of the deficits.\n\n**Current Evidence**\n\nRecent trials such as CHANCE and POINT have demonstrated the benefit of short-term DAPT in reducing recurrent stroke in patients with minor, non-disabling ischemic strokes, influencing current guideline recommendations to personalize therapy based on the functional impact rather than solely on the NIHSS score.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "id": 334,
    "question": "Case of right ICA dissection presented with left sided weakness, what is the treatment in acute setting?",
    "option_a": "stenting",
    "option_b": "angioplasty",
    "option_c": "Medical therapy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nCarotid artery dissection, particularly of the internal carotid artery (ICA), is a common cause of stroke in younger patients. It results from a tear in the arterial wall, leading to the formation of an intramural hematoma and risk of thromboembolism. The standard approach in the acute setting is to prevent thromboembolic complications using medical therapy.\n\n**Pathophysiology**\n\nDissection involves a tear in the intimal layer of the artery, allowing blood to enter the vessel wall which creates a false lumen. This can lead to luminal stenosis and an increased risk of thrombus formation, which may embolize and cause cerebral infarction. The main goal of treatment is to prevent further thromboembolic events.\n\n**Clinical Correlation**\n\nPatients with ICA dissection often present with ipsilateral headache, Horner\u2019s syndrome, or neck pain, and may develop neurological deficits (such as contralateral weakness) due to cerebral ischemia caused by emboli. Recognizing the dissection early is key to preventing stroke progression.\n\n**Diagnostic Approach**\n\nDiagnosis is typically established by imaging modalities such as CT angiography or MRI/MRA. Differential diagnoses include atherosclerotic disease, fibromuscular dysplasia, and other vasculopathies. The imaging findings along with clinical presentation help confirm the diagnosis of arterial dissection.\n\n**Management Principles**\n\nFirst-line management for ICA dissection is medical therapy using either antiplatelet agents or anticoagulation. Current evidence, including the CADISS trial, has not shown a significant difference in outcomes between the two modalities. The selection depends on individual patient risks and contraindications. Endovascular interventions such as stenting or angioplasty are reserved for cases that fail medical management or in which there is ongoing ischemia. In pregnancy and lactation, heparin (as unfractionated heparin or low molecular weight heparin) is generally preferred due to its safety profile.\n\n**Option Analysis**\n\nOption C (Medical therapy) is the correct initial treatment for acute carotid artery dissection. Option A (Stenting) and Option B (Angioplasty) are invasive procedures generally considered in refractory cases or if there is significant luminal compromise causing ongoing ischemia, but they are not first-line treatments.\n\n**Clinical Pearls**\n\n1) Early diagnosis of carotid dissection is essential to prevent thromboembolic stroke. 2) Both antiplatelet and anticoagulant therapies are viable first-line options. 3) Endovascular interventions are considered only if medical therapy fails.\n\n**Current Evidence**\n\nRecent research, including the CADISS trial, has supported the use of medical management (either antiplatelet or anticoagulation) in carotid dissection, with similar efficacy in preventing recurrent ischemic events. This evidence underpins current therapeutic guidelines.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "id": 335,
    "question": "Sickler patient with multiple previous strokes, what is the most important preventitive Rx?",
    "option_a": "Chronic transfusion",
    "option_b": "Aspirin",
    "option_c": "Anticoagulation",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nPatients with sickle cell disease (SCD) are at high risk for ischemic stroke due to the abnormal morphology of red blood cells leading to vascular occlusion and endothelial damage. For secondary prevention in SCD patients who have experienced a stroke, reducing the proportion of sickled red blood cells is key.\n\n**Pathophysiology**\n\nIn SCD, the abnormal hemoglobin S polymerizes under conditions of low oxygen tension, causing red blood cells to sickle. These sickled cells can obstruct microvasculature and cause endothelial injury, which results in a prothrombotic state and predisposes to stroke. Chronic transfusion therapy reduces the proportion of hemoglobin S by diluting it with normal hemoglobin, thereby mitigating these risks.\n\n**Clinical Correlation**\n\nSCD patients with a history of strokes typically present with recurrent neurological deficits and other complications of vaso-occlusion. Stroke prevention is a major component of the overall management strategy in SCD to reduce mortality and morbidity.\n\n**Diagnostic Approach**\n\nEvaluation includes neuroimaging (MRI, MRA) to assess for prior infarcts and ongoing cerebrovascular disease, as well as transcranial Doppler ultrasound screening in children with SCD. Differential diagnoses include transient ischemic attack (TIA) and silent cerebral infarcts, which are common in SCD.\n\n**Management Principles**\n\nChronic red blood cell transfusion is the first-line preventive strategy for secondary stroke prevention in patients with SCD. The goal is to maintain the percentage of hemoglobin S below 30% to lower the risk of recurrent strokes. First-line management includes regular transfusion regimens with appropriate iron chelation to prevent iron overload. Aspirin or anticoagulation is not considered sufficient for stroke prevention in these patients. In pregnancy and lactation, chronic transfusion plans are continued with careful monitoring of iron levels and fetal well-being, as transfusions are generally considered safe.\n\n**Option Analysis**\n\nOption A (Chronic transfusion) is correct as it is the standard of care for preventing recurrent strokes in SCD. Option B (Aspirin) and Option C (Anticoagulation) do not address the underlying pathophysiology of sickling and are not recommended as primary preventive strategies in this population.\n\n**Clinical Pearls**\n\n1) Maintaining hemoglobin S levels below target thresholds is crucial for stroke prevention in SCD. 2) Iron overload is an important complication to monitor in patients on chronic transfusion therapy. 3) Regular neurovascular screening is recommended in children with SCD to preemptively address stroke risk.\n\n**Current Evidence**\n\nRecent guidelines from hematology societies underscore the importance of chronic transfusion therapy for secondary stroke prevention in SCD. Emerging research is also examining the roles of hydroxyurea and stem cell transplantation, but chronic transfusions remain the cornerstone of management for patients with prior strokes.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "id": 336,
    "question": "Case of malignant MCA and presented after 24 hours with midline shift what is the most important thing to do?",
    "option_a": "decompressive cranectomy",
    "option_b": "admission to stroke unit",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nMalignant middle cerebral artery (MCA) infarction is characterized by a large territory stroke that leads to significant cerebral edema, increased intracranial pressure, and often, midline brain shift. Timely surgical intervention can be life-saving in these cases.\n\n**Pathophysiology**\n\nMassive infarction in the MCA territory leads to cytotoxic and vasogenic edema. As the swelling increases, intracranial pressure rises, potentially resulting in brain herniation. Decompressive hemicraniectomy (or craniectomy) is performed to physically allow the swollen brain tissue to expand, thereby reducing intracranial pressure and preventing fatal herniation.\n\n**Clinical Correlation**\n\nPatients with malignant MCA infarction typically have rapidly deteriorating neurological function, and imaging may reveal a large infarct with significant edema and midline shift. If not promptly managed, these patients are at high risk for herniation and death.\n\n**Diagnostic Approach**\n\nDiagnosis is based on clinical presentation and neuroimaging (CT/MRI) showing extensive infarction involving the MCA territory, significant cerebral edema, and midline shift. Differential diagnoses include large hemorrhagic strokes and other causes of cerebral edema, but the context of infarction guides the diagnosis.\n\n**Management Principles**\n\nThe mainstay of treatment is decompressive hemicraniectomy. First-line management involves early surgical intervention, ideally within 48 hours of stroke onset, as studies have demonstrated improved survival and functional outcomes. Supportive care in a stroke unit is also essential, but in the presence of significant midline shift and malignant edema, prompt decompressive surgery takes precedence. In pregnancy and lactation, decompressive craniectomy is similarly indicated when life-threatening cerebral edema is present; however, multidisciplinary collaboration including obstetrics is needed to balance maternal and fetal risks.\n\n**Option Analysis**\n\nOption A (Decompressive craniectomy) is the correct and most urgent intervention in malignant MCA syndrome with midline shift. Option B (Admission to stroke unit) is important for supportive care, but it does not address the life-threatening increase in intracranial pressure. In this emergency setting, surgical decompression is critical.\n\n**Clinical Pearls**\n\n1) Decompressive surgery should be performed within 48 hours of stroke onset for optimal outcomes in malignant MCA infarction. 2) Rapid identification of cerebral edema and midline shift on imaging is crucial. 3) Multidisciplinary care is essential, especially in special populations such as pregnant patients.\n\n**Current Evidence**\n\nRecent randomized controlled trials and meta-analyses support early decompressive hemicraniectomy in reducing mortality and improving outcomes in malignant MCA infarction. Guidelines continue to endorse surgical decompression in patients with significant midline shift, even when presentation is beyond the very early hours, provided the window (usually up to 48 hours) is respected.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "id": 337,
    "question": "SCA causes?",
    "option_a": "Ipsilateral hornors/ptosis",
    "option_b": "Ipsilateral fourth nerve palsy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThe Superior Cerebellar Artery (SCA) supplies portions of the superior cerebellum and parts of the rostral brainstem. Infarction or pathology in this vascular territory can affect both cerebellar structures and adjacent midbrain areas including cranial nerve nuclei or their fiber tracts.\n\n**Pathophysiology**\n\nIschemia in the SCA territory may extend to parts of the midbrain where the trochlear nerve (cranial nerve IV) courses near the dorsal aspect. Disruption of blood flow can lead to infarction of these areas and result in an ipsilateral fourth nerve palsy. In contrast, symptoms such as Horner\u2019s syndrome (ptosis with miosis) are more characteristic of lesions affecting the lateral medulla (PICA territory) or sympathetic pathways.\n\n**Clinical Correlation**\n\nPatients with SCA involvement typically present with cerebellar signs like ataxia and dysmetria. When the infarct affects adjacent midbrain regions, additional findings like an ipsilateral fourth nerve palsy (leading to vertical diplopia or difficulty with downward gaze) can occur.\n\n**Diagnostic Approach**\n\nDiagnosis is established with neuroimaging such as MRI with diffusion-weighted imaging and MR angiography to delineate the vascular territory. Differential diagnoses include lateral medullary syndrome (which may present with ipsilateral Horner\u2019s syndrome), and other brainstem or cerebellar strokes. Careful evaluation of clinical signs coupled with imaging findings helps differentiate these entities.\n\n**Management Principles**\n\nAcute management follows ischemic stroke guidelines including rapid neuroimaging, possible thrombolysis if within the therapeutic window, and secondary prevention measures (antiplatelet agents, control of risk factors). If there is extension into brainstem regions, supportive care and monitoring in a stroke unit are essential. In pregnant and lactating patients, decisions regarding thrombolysis require balancing maternal and fetal risks, but protocols exist to guide safe management.\n\n**Option Analysis**\n\nOption A (Ipsilateral Horner\u2019s syndrome/ptosis) is more typical of lateral medullary (PICA) infarcts affecting sympathetic fibers. Option B (Ipsilateral fourth nerve palsy) reflects involvement of midbrain areas near the SCA territory, making it the more appropriate answer in this context.\n\n**Clinical Pearls**\n\n1. SCA infarcts classically present with cerebellar ataxia and may include ocular motor deficits when adjacent midbrain structures are involved. 2. Horner\u2019s syndrome is usually seen with lesions in the posterior inferior cerebellar artery (PICA) distribution. 3. Detailed neuroimaging is essential to appropriately localize posterior circulation strokes.\n\n**Current Evidence**\n\nRecent literature emphasizes the importance of early multimodal imaging in posterior circulation strokes to direct acute management. Guidelines continue to support thrombolytic therapy following strict criteria, and emerging evidence highlights the role of endovascular techniques in select cases.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "id": 338,
    "question": "Scenario about patient with my Moyamoya syndrome and history of ischemic stroke, what is the best treatment to prevent future stroke?",
    "option_a": "Chronic transfusion",
    "option_b": "Aspirin and clopidogrel",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nMoyamoya syndrome is characterized by progressive stenosis or occlusion of the terminal portions of the internal carotid arteries, with the formation of a network of fragile collateral vessels. This chronic process predisposes patients to ischemic strokes and, less commonly, hemorrhagic events.\n\n**Pathophysiology**\n\nThe progressive narrowing of major intracranial arteries leads to reduced cerebral perfusion. The compensatory development of collateral vessels (which appear as a \u201cpuff of smoke\u201d on angiography) is often insufficient to meet metabolic demands. This mismatch predisposes patients to recurrent ischemic events. The definitive treatment addresses the hemodynamic compromise by surgically improving cerebral blood flow through revascularization.\n\n**Clinical Correlation**\n\nPatients with Moyamoya syndrome often present with transient ischemic attacks or strokes, and may have a history of prior ischemic events. Ischemic symptoms, such as weakness or speech difficulties, are common. The risk of future stroke remains high without definitive intervention.\n\n**Diagnostic Approach**\n\nDiagnosis is confirmed with imaging such as MRI/MRA or conventional angiography, which reveals the characteristic vasculature. Differential diagnoses include other causes of intracranial arterial stenosis (e.g., atherosclerosis, vasculitis) and genetic conditions that predispose to stroke. Characteristic findings on angiography help differentiate Moyamoya from these other conditions.\n\n**Management Principles**\n\nThe primary treatment to prevent future stroke in Moyamoya is surgical revascularization. First-line surgical options include direct bypass (e.g., superficial temporal artery to middle cerebral artery [STA-MCA] bypass) or indirect revascularization procedures (e.g., encephaloduroarteriosynangiosis [EDAS]). Medical management with antiplatelets may be used as an adjunct or bridge while awaiting surgery, but is not sufficient on its own. In patients with sickle cell disease\u2013associated Moyamoya, chronic transfusion therapy may be considered, but this is not typical for non\u2013sickle cell Moyamoya. In pregnancy and lactation, surgical procedures are approached with caution; if indicated, a multidisciplinary team should evaluate the timing and risk, with medical therapy (including low-dose aspirin) possibly used during gestation under close monitoring.\n\n**Option Analysis**\n\nOption A (Chronic transfusion) is primarily used in sickle cell disease\u2013associated stroke prevention, not in primary Moyamoya syndrome. Option B (Aspirin and clopidogrel) suggests dual antiplatelet therapy, which is not the standard definitive treatment for Moyamoya. Option C, presumed to stand for surgical revascularization, is the best treatment to prevent future strokes in this context.\n\n**Clinical Pearls**\n\n1. Surgical revascularization is the treatment of choice for prevention of recurrent stroke in Moyamoya syndrome. 2. Moyamoya should be suspected in patients (especially in children and young adults) with recurrent ischemic events and characteristic angiographic findings. 3. Comprehensive management may require coordination across neurology, neurosurgery, and, when relevant, hematology (in sickle cell disease).\n\n**Current Evidence**\n\nRecent guidelines and studies from stroke and neurosurgical societies continue to support early revascularization in symptomatic Moyamoya to improve long\u2010term outcomes. Advances in surgical techniques and perioperative care have further optimized outcomes in both pediatric and adult populations.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "id": 339,
    "question": "Patient on Warfarin developed weakness, CT brain attached showed intracranial bleeding with fluid level feature, what is the cause?",
    "option_a": "Coagulopathy",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nPatients on warfarin are at risk for hemorrhagic complications due to its anticoagulant effect. Warfarin interferes with the synthesis of vitamin K dependent clotting factors, predisposing patients to bleeding.\n\n**Pathophysiology**\n\nWarfarin-induced coagulopathy leads to impaired clot formation. In the event of intracranial bleeding, the lack of effective coagulation can result in blood layering, creating a fluid\u2013fluid level on CT imaging. The fluid level signifies that the blood components have separated due to inadequate clot stabilization.\n\n**Clinical Correlation**\n\nA patient on warfarin who develops sudden weakness and is found to have intracranial bleeding on CT should raise suspicion for a coagulopathy-induced hemorrhage. The presence of a fluid level on imaging supports the diagnosis of a bleeding diathesis rather than a typical hemorrhagic stroke resulting solely from hypertension.\n\n**Diagnostic Approach**\n\nCT imaging is the first modality to assess intracranial hemorrhage. Laboratory tests including PT/INR are critical to evaluate the degree of anticoagulation. Differential diagnoses include hypertensive hemorrhage and hemorrhagic conversion of an ischemic stroke; however, the fluid level is particularly suggestive of a coagulopathic bleed as seen with warfarin over-anticoagulation.\n\n**Management Principles**\n\nManagement involves rapid reversal of warfarin\u2019s effects using vitamin K and prothrombin complex concentrates (or fresh frozen plasma, if PCC is unavailable). Blood pressure control and supportive care are also essential. In pregnancy and lactation, reversal agents must be used cautiously; for example, vitamin K is generally safe, but FFP and PCC should be administered with considerations for both maternal and fetal health. Monitoring of coagulation parameters following reversal is critical.\n\n**Option Analysis**\n\nOption A (Coagulopathy) is correct because warfarin causes a bleeding diathesis leading to intracranial hemorrhage with characteristic imaging findings. The other options (B, C, D) are either not provided or are less likely to explain the CT fluid level seen in this scenario.\n\n**Clinical Pearls**\n\n1. Warfarin\u2019s anticoagulant effect increases the risk of intracranial hemorrhage, often with a characteristic fluid\u2013fluid level on CT due to poor clot formation. 2. Always verify coagulation parameters (INR/PT) in patients on warfarin presenting with new neurological symptoms. 3. Rapid reversal of anticoagulation is crucial to minimize further bleeding complications.\n\n**Current Evidence**\n\nRecent evidence emphasizes the use of PCC for rapid warfarin reversal, with updated guidelines advocating for tailored reversal strategies based on the severity of bleeding and INR levels. Studies continue to refine the risk/benefit profiles of various reversal agents, especially in patients with concurrent comorbidities.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "id": 340,
    "question": "Patient presented with right face, arm and leg weakness with mild articulation difficulties, where is the localization of his lesion?",
    "option_a": "Internal capsule",
    "option_b": "Midbrain",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThe internal capsule, particularly its posterior limb, is a compact area where corticospinal and corticobulbar fibers converge. A lesion here can produce a contralateral, often complete, motor deficit affecting the face, arm, and leg.\n\n**Pathophysiology**\n\nA lacunar infarct or other small vessel occlusion in the internal capsule damages the densely packed motor fibers, leading to pure motor hemiparesis. The involvement of corticobulbar fibers can also result in mild dysarthria (articulation difficulties).\n\n**Clinical Correlation**\n\nPatients presenting with weakness affecting the contralateral face, arm, and leg, along with slight speech articulation problems, are classic for an internal capsule lesion. There is typically no significant sensory deficit, which helps differentiate it from strokes involving other areas.\n\n**Diagnostic Approach**\n\nMagnetic resonance imaging (MRI) and CT scans are used to localize the infarct. Differential diagnoses include middle cerebral artery (MCA) strokes, which often produce additional cortical signs, and brainstem strokes, which can also produce lower cranial nerve involvement. The pure motor pattern favors a lacunar infarct in the internal capsule.\n\n**Management Principles**\n\nAcute management involves standard ischemic stroke protocols, including consideration of thrombolytic therapy if within the window period and secondary prevention with antiplatelet agents and risk factor modification. In pregnant or lactating patients, management of stroke follows established protocols with particular attention to medication safety (e.g., aspirin is generally considered safe in low doses; thrombolysis can be considered if benefits outweigh risks). Long-term management focuses on controlling vascular risk factors to prevent recurrence.\n\n**Option Analysis**\n\nOption A (Internal capsule) is correct because it best accounts for the presentation of pure motor deficits involving the face, arm, and leg with mild dysarthria. Option B (Midbrain) is less likely because midbrain lesions often involve additional cranial nerve deficits or altered consciousness, which are not described here.\n\n**Clinical Pearls**\n\n1. The classic \u201cpure motor stroke\u201d syndrome is most commonly due to a lacunar infarct in the posterior limb of the internal capsule. 2. Small, deep infarcts often occur in patients with chronic vascular risk factors like hypertension and diabetes. 3. Rapid imaging and risk factor control are key to optimizing outcomes in lacunar strokes.\n\n**Current Evidence**\n\nCurrent stroke guidelines emphasize early identification and management of lacunar strokes, with studies supporting intensive risk factor modification to reduce the risk of recurrent events. Research into advanced imaging techniques continues to improve our ability to localize small deep infarcts.",
    "exam_year": "2024",
    "exam_type": "Part II"
  }
]